Myriad Genetics logo

Myriad Genetics Share Price Today

(NASDAQ: MYGN)

Myriad Genetics share price is $7.64 & ₹652.95 as on 17 Apr 2025, 09.30 hrs IST

$7.64

-0.27

(-3.41%)

Market is closed - opens 7 PM, 21 Apr 2025

View live Myriad Genetics share price in Dollar and Rupees. Guide to invest in Myriad Genetics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Myriad Genetics, along with analyst recommendations, forecasts, and comprehensive financials.

Myriad Genetics share price movements

  • Today's Low: $7.58
    Today's High: $7.93

    Day's Volatility :4.41%

  • 52 Weeks Low: $7.35
    52 Weeks High: $29.30

    52 Weeks Volatility :74.91%

Myriad Genetics (MYGN) Returns

PeriodMyriad Genetics Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-39.22%
-3.3%
0.0%
6 Months
-66.1%
-11.5%
0.0%
1 Year
-58.7%
-2.5%
0.0%
3 Years
-65.1%
-2.1%
-12.9%

Myriad Genetics (MYGN) Key Statistics

in dollars & INR

Previous Close
$7.91
Open
$7.86
Today's High
$7.93
Today's Low
$7.58
Market Capitalization
$729.1M
Today's Volume
$1.6M
52 Week High
$29.3
52 Week Low
$7.35
Revenue TTM
$837.6M
EBITDA
$-26.8M
Earnings Per Share (EPS)
$-1.41
Profit Margin
-15.2%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-17.15%

How to invest in Myriad Genetics Stock (MYGN) from India?

It is very easy for Indian residents to invest directly in Myriad Genetics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Myriad Genetics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Myriad Genetics or MYGN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Myriad Genetics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Myriad Genetics shares which would translate to 0.112 fractional shares of Myriad Genetics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Myriad Genetics, in just a few clicks!

Returns in Myriad Genetics (MYGN) for Indian investors in Rupees

The Myriad Genetics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Myriad Genetics investment value today

Current value as on today

₹43,638

Returns

₹56,362

(-56.36%)

Returns from Myriad Genetics Stock

₹58,703 (-58.7%)

Dollar Returns

₹2,341 (+2.34%)

Indian investors sentiment towards Myriad Genetics (MYGN)

-57%

Period: Mar 19, 2025 to Apr 18, 2025. Change in 30 Days versus previous period

Search interest for Myriad Genetics Stock from India on INDmoney has decreased by -57% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Myriad Genetics

  • BlackRock Inc

    17.42%

  • Vanguard Group Inc

    11.60%

  • Wellington Management Company LLP

    6.58%

  • State Street Corp

    6.05%

  • Millennium Management LLC

    4.76%

  • Glenview Capital Management LLC

    4.55%

Analyst Recommendation on Myriad Genetics

Rating
Trend

Buy

    50%Buy

    33%Hold

    16%Sell

Based on 18 Wall street analysts offering stock ratings for Myriad Genetics(by analysts ranked 0 to 5 stars)

Analyst Forecast on Myriad Genetics Stock (MYGN)

What analysts predicted

Upside of 109.51%

Target:

$16.01

Current:

$7.64

Insights on Myriad Genetics Stock (Ticker Symbol: MYGN)

  • Price Movement

    In the last 6 months, MYGN stock has moved down by -67.3%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 213.3M → 210.6M (in $), with an average decrease of 1.3% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -22.1M → -42.5M (in $), with an average decrease of 92.3% per quarter
  • MYGN vs IDXX (1 yr)

    In the last 1 year, Myriad Genetics Inc. has experienced a drawdown of -58.7%, however Idexx Laboratories, Inc. resisted the overall trend and outperformed by 45.1%
  • MYGN vs IDXX (3 yr)

    In the last 3 years, Myriad Genetics Inc. has experienced a drawdown of -66.8%, however Idexx Laboratories, Inc. resisted the overall trend and outperformed by 49.0%
  • Price to Sales

    ForMYGN every $1 of sales, investors are willing to pay $0.8, whereas for Idexx Laboratories, Inc., the investors are paying $8.7 for every $1 of sales.

Myriad Genetics Technicals Summary

Sell

Neutral

Buy

Myriad Genetics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Myriad Genetics (MYGN) Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Myriad Genetics Inc. logo
-22.91%
-66.1%
-58.7%
-65.1%
-49.74%
Agilent Technologies Inc. logo
-14.8%
-25.07%
-22.79%
-20.79%
32.45%
Idexx Laboratories, Inc. logo
-2.17%
-9.24%
-13.62%
-19.85%
53.92%
Thermo Fisher Scientific, Inc. logo
-17.57%
-28.2%
-21.53%
-27.68%
30.67%
Danaher Corp. logo
-11.14%
-31.34%
-20.67%
-33.37%
19.89%
Iqvia Holdings Inc. logo
-21.9%
-37.75%
-36.91%
-40.72%
12.86%

Myriad Genetics Dividend announcements

  • Myriad Genetics Earnings

    Myriad Genetics’s price-to-earnings ratio stands at None

About Myriad Genetics

Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Organization
Myriad Genetics
Employees
2700
CEO
Mr. Paul J. Diaz J.D.
Industry
Health Technology

Management People of Myriad Genetics

NameTitle
Mr. Paul J. Diaz J.D.
CEO, President & Director
Mr. Scott J. Leffler
Chief Financial Officer
Mr. Samraat S. Raha
Chief Operating Officer
Dr. Dale Muzzey Ph.D.
Chief Scientific Officer
Mr. Mark S. Verratti
Chief Commercial Officer
Ms. Natalie Munk
Senior VP & Chief Accounting Officer
Dr. Kevin Richard Haas Ph.D.
Chief Technology Officer
Mr. Matthew Scalo
Senior Vice President of Investor Relations
Ms. Jennifer L. Fox J.D.
Chief Legal Officer
Ms. Shereen Solaiman
Chief People Officer

Important FAQs about investing in MYGN Stock from India :

What is Myriad Genetics share price today?

Myriad Genetics share price today stands at $7.64, Open: $7.86 ; Previous Close: $7.91 ; High: $7.93 ; Low: $7.58 ; 52 Week High: $29.30 ; 52 Week Low: $7.35.

The stock opens at $7.86, after a previous close of $7.91. The stock reached a daily high of $7.93 and a low of $7.58, with a 52-week high of $29.30 and a 52-week low of $7.35.

Can Indians buy Myriad Genetics shares?

Yes, Indians can invest in the Myriad Genetics (MYGN) from India.

With INDmoney, you can buy Myriad Genetics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Myriad Genetics at zero transaction cost.

How can I buy Myriad Genetics shares from India?

It is very easy to buy Myriad Genetics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Myriad Genetics (MYGN) be purchased?

Yes, you can buy fractional shares of Myriad Genetics with INDmoney app.

What are the documents required to start investing in Myriad Genetics stocks?

To start investing in Myriad Genetics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Myriad Genetics Stock (MYGN)?

Today’s highest price of Myriad Genetics (MYGN) is $7.93.

Today’s lowest price of Myriad Genetics (MYGN) is $7.58.

What is today's market capitalisation of Myriad Genetics?

Today's market capitalisation of Myriad Genetics MYGN is 729.1M

What is the 52 Week High and Low Range of Myriad Genetics Stock (MYGN)?

  • 52 Week High

    $29.30

  • 52 Week Low

    $7.35

What are the historical returns of Myriad Genetics (MYGN)?

  • 1 Month Returns

    -22.91%

  • 3 Months Returns

    -66.1%

  • 1 Year Returns

    -58.7%

  • 5 Years Returns

    -49.74%

Who is the Chief Executive Officer (CEO) of Myriad Genetics ?

Mr. Paul J. Diaz J.D. is the current Chief Executive Officer (CEO) of Myriad Genetics.